Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Howell

Showing results (101-110 of 339) with videos related to

Pageof 34
Sort By:
Cell Cycle (Georgetown, Tex.)|August 31, 2013
Stromal glycolysis and MCT4 are hallmarks of DCIS progression to invasive breast cancerMichael P Lisanti, Federica Sotgia, Richard G Pestell, et al.
British Journal of Cancer|January 26, 2021
Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trialIvana Sestak, Glen Blake, Raj Patel, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|March 16, 2007
The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptidesAndrew G Renehan, Jan Frystyk, Anthony Howell, et al.
Familial Cancer|April 13, 2007
Adult weight gain and central obesity in women with and without a family history of breast cancer: a case control studyMichelle N Harvie, Saba Bokhari, Andrew Shenton, et al.
Cancers|June 2, 2021
Is Breast Cancer Risk Associated with Menopausal Hormone Therapy Modified by Current or Early Adulthood BMI or Age of First Pregnancy?Eleni Leventea, Elaine F Harkness, Adam R Brentnall, et al.
Journal of the National Cancer Institute|February 22, 2007
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trialJack Cuzick, John F Forbes, Ivana Sestak, et al.
The Lancet. Oncology|September 5, 2008
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II)Valerie A Jenkins, Laurence M Ambroisine, Louise Atkins, et al.
The Lancet. Oncology|November 20, 2010
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialJack Cuzick, Ivana Sestak, Michael Baum, et al.
BJC Reports|November 8, 2024
Weight, weight gain and behavioural risk factors in women attending a breast cancer family history, risk and prevention clinic: an observational studyMary Pegington, John Belcher, Emma Barrett, et al.
The Lancet. Oncology|December 16, 2014
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trialJack Cuzick, Ivana Sestak, Simon Cawthorn, et al.
Pageof 34

Showing results (101-110 of 339) with videos related to

Sort By:
Pageof 34
Cell Cycle (Georgetown, Tex.)|August 31, 2013
Stromal glycolysis and MCT4 are hallmarks of DCIS progression to invasive breast cancerMichael P Lisanti, Federica Sotgia, Richard G Pestell, et al.
British Journal of Cancer|January 26, 2021
Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trialIvana Sestak, Glen Blake, Raj Patel, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|March 16, 2007
The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptidesAndrew G Renehan, Jan Frystyk, Anthony Howell, et al.
Familial Cancer|April 13, 2007
Adult weight gain and central obesity in women with and without a family history of breast cancer: a case control studyMichelle N Harvie, Saba Bokhari, Andrew Shenton, et al.
Cancers|June 2, 2021
Is Breast Cancer Risk Associated with Menopausal Hormone Therapy Modified by Current or Early Adulthood BMI or Age of First Pregnancy?Eleni Leventea, Elaine F Harkness, Adam R Brentnall, et al.
Journal of the National Cancer Institute|February 22, 2007
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trialJack Cuzick, John F Forbes, Ivana Sestak, et al.
The Lancet. Oncology|September 5, 2008
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II)Valerie A Jenkins, Laurence M Ambroisine, Louise Atkins, et al.
The Lancet. Oncology|November 20, 2010
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialJack Cuzick, Ivana Sestak, Michael Baum, et al.
BJC Reports|November 8, 2024
Weight, weight gain and behavioural risk factors in women attending a breast cancer family history, risk and prevention clinic: an observational studyMary Pegington, John Belcher, Emma Barrett, et al.
The Lancet. Oncology|December 16, 2014
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trialJack Cuzick, Ivana Sestak, Simon Cawthorn, et al.
Pageof 34